SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Understanding Preschool Projects: An Extensive Aide - 2Space station changes command, setting stage for Crew 11 departure
- 3Home Mechanization Frameworks for Brilliant Residing
- 4Air Force made critical errors during October 7 massacre, investigator says
- 5Hamas set to elect new terror leader with Hayya, Mashaal in pole position
- Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- Israeli media reports Iran attacking greater Tel Aviv region
- 4 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- An Investigate of 6 Creative Specialty Mixed drinks
- Washington resident is infected with a different type of bird flu
